莫迪向美国屈服，损害中方利益当投名状，不料我商务部出手更快

Group 1 - India proposed a "zero-for-zero" tariff arrangement for specific goods, including steel, auto parts, and pharmaceuticals, during trade negotiations with the US, contingent on reciprocity and limited to a certain quantity of imports [1] - The US has concerns regarding India's quality control measures, viewing them as non-tariff trade barriers, while a 10% baseline tariff remains in effect despite the suspension of a 26% "reciprocal tariff" [1] - India's exports of pharmaceuticals to the US have exceeded $10.5 billion, and engineering products reached $19.1 billion, yet the US maintains a trade deficit of $45.7 billion with India [1] Group 2 - The US Treasury Secretary indicated that India could be the fastest country to reach a trade agreement with the US, although skepticism remains regarding the actual progress of negotiations [3] - The Chinese Ministry of Commerce initiated an anti-dumping investigation against Indian imports of chlorpyrifos, concluding that dumping occurred and caused substantial harm to the domestic industry [3] Group 3 - India has significantly increased its chlorpyrifos exports to China, with a 75.79% rise in volume from 2019 to 2023, while the price per ton dropped by 42.07%, leading to a decline in market share for Chinese producers [5] - The market share of Indian chlorpyrifos in China rose from 49% to 71.47% over the same period, causing financial distress for Chinese manufacturers [5] Group 4 - India has shown a tendency to balance its relationships, often leading to conflicts within BRICS, as evidenced by its absence from a recent BRICS foreign ministers' meeting [7] - The announcement of anti-dumping measures by China against India serves as a warning to protect its own interests amid these trade dynamics [7]